The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mynucleus.com

Founded Year

2021

Stage

Seed VC - II | Alive

Total Raised

$17.5M

Last Raised

$14M | 1 mo ago

Mosaic Score

+130 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Nucleus Genomics

Nucleus Genomics allows users to upload their genetic information obtained through an established company, like 23andMe or Ancestry, or order a genetic testing kit. Then the company’s “proprietary algorithms” will calculate polygenic risk scores – a measure of disease risk based on analysis of genetic variants – and display them in a user-friendly platform. Nucleus Genomics was founded in 2021 and is based in New York, New York.

Nucleus Genomics Headquarters Location

584 Broadway

New York, New York, 10012,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nucleus Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nucleus Genomics is included in 1 Expert Collection, including Omics.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest Nucleus Genomics News

Nucleus Genomics Acquires Polygenic Risk Score Tool

Jul 28, 2022

Save for later CHICAGO – Nucleus Genomics has acquired Impute.me, a formerly open-source software tool for calculating polygenic risks scores from direct-to-consumer genetic tests, for an undisclosed amount. The company has also hired Impute.me creator Lasse Folkersen as CSO. "Impute.me will be selectively integrated in with our existing novel genetic analysis technology, further bolstering the quality and rigor of our analyses," Nucleus Genomics Founder and CEO Kian Sadeghi said  in an email. The acquisition happened on the same day that Nucleus announced the closing of a $14 million "seed-plus" funding round . The New York-based company simultaneously introduced a beta version of a consumer-facing genetic testing software platform that will underpin its strategy to create polygenic risk scores and give individuals control of their genetic data. The direct-to-consumer data analysis company plans on offering whole-genome sequencing to the public in the future through laboratory partners. Folkersen led the development of Impute.me at Sankt Hans Hospital in Roskilde, Denmark, starting in 2015 and was the lead author on a 2020 publication describing the tool. In a July 14 tweet, Folkersen said that Impute.me "would have eventually succumbed to the ever increasing regulatory environment in the EU (e.g. IVDR), because running things like that as a one-man operation simply is not feasible in the long run." The European Union's new In Vitro Diagnostics Regulation (IVDR) took effect in May. "I've learned the hard way that to actually get stuff done, one must have a commercial organization and a flow of money to employ and empower that organization," Folkersen tweeted in the same thread . "My goal is, and always has been, to make genetic information easier to use for the health benefits of regular people, and to lower the barriers to access."

Nucleus Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nucleus Genomics Rank

  • When was Nucleus Genomics founded?

    Nucleus Genomics was founded in 2021.

  • Where is Nucleus Genomics's headquarters?

    Nucleus Genomics's headquarters is located at 584 Broadway, New York.

  • What is Nucleus Genomics's latest funding round?

    Nucleus Genomics's latest funding round is Seed VC - II.

  • How much did Nucleus Genomics raise?

    Nucleus Genomics raised a total of $17.5M.

  • Who are the investors of Nucleus Genomics?

    Investors of Nucleus Genomics include Founders Fund, Shrug Capital, Austin Allred, Seven Seven Six, Packy McCormick and 16 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.